A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping
Conditions
- Muscular Dystrophies
- Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)
- Muscular Disorders, Atrophic
- Muscular Disease
- Musculoskeletal Diseases
- Neuromuscular Diseases (NMD)
- Nervous System Diseases
- Genetic Diseases
- X-Linked
- Hereditary
- Neonatal Disease
- Duchene Muscular Dystrophy
- Congenital
- DMD
Interventions
- DRUG: AOC 1044
- DRUG: Placebo
Sponsor
Avidity Biosciences, Inc.